Contrast-enhanced endoscopic ultrasound for differential diagnosis of pancreatic cancer: an updated meta-analysis

Xing-Kang He, Yue Ding and Lei-Min Sun _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:66392-66401. https://doi.org/10.18632/oncotarget.18915

Metrics: PDF 1806 views  |   HTML 2339 views  |   ?  


Xing-Kang He1,2,*, Yue Ding1,2,* and Lei-Min Sun1,2

1Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University Medical School, Hangzhou 310016, China

2Institute of Gastroenterology, Zhejiang University, Hangzhou 310016, China

*These authors contributed equally to this work

Correspondence to:

Lei-Min Sun, email: [email protected]

Keywords: contrast-enhanced EUS, contrast-enhanced doppler EUS, contrast-enhanced harmonic EUS, pancreatic adenocarcinomas

Received: July 10, 2016     Accepted: June 18, 2017     Published: July 01, 2017


Aim: We aim to assess the diagnostic value of contrast-enhanced endoscopic ultrasound (CE-EUS) for pancreatic cancer and inflammatory lesions by pooling current evidence.

Materials and Methods: A systematical search of PubMed, Web of Science and the Cochrane Library was performed from inception to January 2016. Two authors independently screened and extracted detailed data from included studies. A random effect model was adopted to estimate the pooled sensitivity, specificity in order to determine the diagnostic ablitity of CE-EUS. Furthermore, we conducted the meta-regression and subgroup analyses to explore possible heterogeneity.

Results: Eighteen eligible studies enrolling 1668 patients were finally included in the study. The pooled sensitivity of CE-EUS for distinguishing pancreatic cancers from solid inflammatory masses was 0.93 (95% CI, 0.91–0.94), and the specificity was 0.88 (95% CI, 0.84–0.90). The area under summary receiver operating characteristic curve yielded 0.97. No publication bias was observed by Deeks’ funnel plot in current meta-analysis.

Conclusions: We provided evidence that CE-EUS is a promising modality for differential diagnosis of pancreatic adenocarcinomas. Further multicenter prospective studies should be carried out to certify its utility.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18915